Adaptive Biotechnologies Corp
ADPTQ2 2024(ADPT Q1 FY2024)Derived11% AI
AI Revenue %
11%
AI Fair Value
$160.9M
AI Revenue (Q)
$4.6M
Total Revenue (Q)
$41.9M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
First quarter with explicit two-segment reporting. Total revenue $41.9M. MRD segment: $32.6M. Immune Medicine segment: $9.2M. Genentech was 13.5% of total revenue = ~$5.7M, meaning ~$5.7M of the $9.2M IM revenue was Genentech collaboration. The IM segment uses AI/ML for TCR-Antigen mapping and drug discovery. Applying 50% AI attribution to IM segment revenue (AI/ML is the enabling technology but deliverable is biological/sequencing services): $9.2M * 50% = $4.6M. AI Revenue % = $4.6M / $41.9M = 11.0%.
Analyzed by claude-opus-4-6
Quoted Figures
MRD Revenue $32,626K, Immune Medicine Revenue $9,247K, Total $41,873K for Q1 2024
10-Q filed 2024-05-08, Segment Information note
Genentech, Inc. and Roche Group 13.5% of revenue
10-Q filed 2024-05-08, Revenue Concentration table
We are applying artificial intelligence and machine learning models to map at scale TCR sequences to the diseases they bind to enable our drug discovery efforts
10-Q filed 2024-05-08, MD&A Overview
AI Products Identified (Ring 1)
TCR-Antigen Map (AI/ML-driven immune receptor-disease mapping)Genentech TCR-based cell therapy collaboration (AI-enabled TCR discovery)Adaptive Immunosequencing (AI/ML analysis component)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test ($32.6M MRD segment, NGS-based)MRD Pharma testing services (sequencing-based)
Confidence Tier
DerivedCalculated from reported segments primarily serving AI